One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis
Pooled result · One-year survival rateResult — go to the resultRR for one-year survival 1.59 95 % CI 0.96–2.65Authors' conclusion
As an adjunctive therapy, PLEX improved one-year survival in IIM patients with rapidly progressive ILD who were unresponsive to standard treatments.
Study context
- Population
- Patients with anti-MDA5-positive DM or antisynthetase syndrome-related DM with rapidly progressive interstitial lung disease (ILD) refractory to standard treatments (GC, immunosuppressive agents or intravenous immunoglobulin)
- Participants
- 148 patients6 cohort studies
- Comparison
- Plasma exchange (PLEX) in addition to other therapies vs non-PLEX
- Outcome
- One-year survival rate
- Follow-up
- One year
Methodological detailssensitivity analysis, Funnel plot asymmetry suggested publication bias, All studies had a low risk of bias
- Sensitivity analysis
- Funnel plot asymmetry suggested publication bias
- All studies had a low risk of bias
Pooled result
As reported in the abstract
RR for one-year survival
1.59
95 % CI 0.96–2.65
PLEXvs non-PLEX
RR for one-year survival 1.59 (95 % CI 0.96–2.65)
Further pooled results
Lung function, radiographic outcomes, KL-6 and ferritin
- Trend suggesting PLEX improved lung function, radiographic outcomes and key serum biomarkers (Krebs von den Lungen-6, ferritin)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
One-year survival benefit of plasma exchange in idiopathic inflammatory myositis patients with progressive interstitial lung disease-a systemic review and meta-analysis. Semin Arthritis Rheum. Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →